Carbamylated erythropoietin outperforms erythropoietin in the treatment of AKI-on-CKD and Other AKI models

Journal of the American Society of Nephrology

Volumn 27, Issue 11, 2016, Pages 3394-3404

  Tögel, Florian E ^a   Ahlstrom, Jon D ^b,c   Yang, Ying ^b   Hu, Zhuma ^b   Zhang, Ping ^b   Westenfelder, Christof ^b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; CD131 ANTIGEN; CREATININE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA; NITROGEN; UNCLASSIFIED DRUG; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEMATOCRIT; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY MASS; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SEX DIFFERENCE; SURVIVAL; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY INJURY; AGE; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; FISCHER 344 RAT; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; AGE FACTORS; ANIMALS; ERYTHROPOIETIN; FEMALE; MALE; RATS; RATS, INBRED F344; RENAL INSUFFICIENCY, CHRONIC; SEX FACTORS;

EID: 85016007090     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015091059     Document Type: Article

References (56)

1. Hsu C-Y, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS: Community-based incidence of acute renal failure. Kidney Int 72: 208-212, 2007
2. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16: 3365-3370, 2005
3. Ricci Z,CruzD, Ronco C: The RIFLE criteria andmortality in acute kidney injury: A systematic review. Kidney Int 73: 538-546, 2008
4. Molitoris BA, Sutton TA: Endothelial injury and dysfunction: Role in the extension phase of acute renal failure. Kidney Int 66: 496-499, 2004
5. Molitoris BA, Falk SA, Dahl RH: Ischemia-induced loss of epithelial polarity. Role of the tight junction. J Clin Invest 84: 1334-1339, 1989
6. Dagher PC: Apoptosis in ischemic renal injury: Roles of GTP depletion and p53. Kidney Int 66: 506-509, 2004
7. Jelkmann W: Erythropoietin after a century of research: Younger than ever. Eur J Haematol 78: 183-205, 2007
8. Hörl WH: Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 9: 291-301, 2013
9. Rossert J, Froissart M, Jacquot C: Anemia management and chronic renal failure progression. Kidney Int Suppl 99: S76-S81, 2005
10. Sasaki R, Masuda S, Nagao M: Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci 16: 110-113, 2001
11. Brines M, Cerami A: Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int 70: 246-250, 2006
12. Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141: 14-31, 2008
13. Westenfelder C, Biddle DL, Baranowski RL: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55: 808-820, 1999
14. Westenfelder C: Unexpected renal actions of erythropoietin. Exp Nephrol 10: 294-298, 2002
15. EchigoyaMH, Obikane K, Nakashima T, Sasaki S: Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron, Exp Nephrol 100: e21-e29, 2005
16. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, LimSW, Sun BK, KimYS, Kim J, Chang YS, Bang BK: Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17: 1754-1755, 2003
17. VaziriND, Zhou XJ, Liao SY: Erythropoietin enhances recovery from cisplatininduced acute renal failure. Am J Physiol 266: F360-F366, 1994
18. Gobe GC, Bennett NC,West M, Colditz P, Brown L, Vesey DA, Johnson DW: Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury. Am J Physiol Renal Physiol 306: F681-F692, 2014
19. Vaziri ND: Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10: 633-637, 2001
20. HenkeM, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B,Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003
21. Smith KJ, Bleyer AJ, Little WC, Sane DC: The cardiovascular effects of erythropoietin. Cardiovasc Res 59: 538-548, 2003
22. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C; EPO Stroke Trial Group: Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40: e647-e656, 2009
23. Robertson CS, Hannay HJ, Yamal J-M, Gopinath S, Goodman JC, Tilley BC, Baldwin A, Rivera Lara L, Saucedo-Crespo H, Ahmed O, Sadasivan S, Ponce L, Cruz-Navarro J, Shahin H, Aisiku IP, Doshi P, Valadka A, Neipert L, Waguspack JM, Rubin ML, Benoit JS, Swank P; Epo Severe TBI Trial Investigators: Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: A randomized clinical trial. JAMA 312: 36-47, 2014
24. LeistM, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie Q-W, Coleman T, Cerami A, Brines M: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242, 2004
25. Coleman TR,WestenfelderC, Tögel FE, Yang Y,HuZ, Swenson L, Leuvenink HGD, Ploeg RJ, d'Uscio LV, Katusic ZS, Ghezzi P, Zanetti A, Kaushansky K, Fox NE, Cerami A, Brines M: Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 103: 5965-5970, 2006
26. BrinesM, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie Q-W, Smart J, Su-Rick C-J, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A: Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101: 14907-14912, 2004
27. Fantacci M, Bianciardi P, Caretti A, Coleman TR, Cerami A, Brines M, Samaja M: Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. ProcNatl Acad Sci U S A 103: 17531-17536, 2006
28. Imamura R, Isaka Y, Ichimaru N, Takahara S,Okuyama A: Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 353: 786-792, 2007
29. Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, Imai E, Nonomura N, Takahara S, Okuyama A: Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemiareperfusion injury. Cell Transplant 17: 135-141, 2008
30. Abe T, Isaka Y, Imamura R, Kakuta Y, Okumi M, Yazawa K, Ichimaru N, Tsuda H, Nonomura N, Takahara S, Okuyama A: Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis. Cell Transplant 21: 571-580, 2012
31. Kitamura H, Isaka Y, Takabatake Y, Imamura R, Suzuki C, Takahara S, Imai E: Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant 23: 1521-1528, 2008
32. Imamura R, Isaka Y, Sandoval RM, Ichimaru N, Abe T, Okumi M, Yazawa K, Kitamura H, Kaimori J,NonomuraN, RakugiH,Molitoris BA, Takahara S: A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. Clin ExpNephrol 16: 852-862, 2012
33. van derWorp HB, Howells DW, Sena ES, PorrittMJ, Rewell S, O'Collins V, Macleod MR: Can animal models of disease reliably inform human studies? PLoS Med 7: e1000245, 2010
34. Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ, Jaber BL: Epidemiology and outcomes of acute renal failure in hospitalized patients: A national survey. Clin J Am Soc Nephrol 1: 43-51, 2006
35. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ: Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J AmSoc Nephrol 17: 1135-1142, 2006
36. Anderson S, Eldadah B, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kimmel PL, Molitoris BA, Murthy M, O'Hare AM, Schmader KE, High KP: Acute kidney injury in older adults. J AmSocNephrol 22: 28-38, 2011
37. Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, Lowry S, Conger J, McKeown W, O'shea M, Baughman R, Wood K, Haupt M, Kaiser R, Simms H,Warnock D, SummerW, Hintz R,Myers B, Haenftling K, Capra W, Pike M, Guler HP: Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 55: 2423-2432, 1999
38. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, Genter FC, Kurnik BR, Conger JD, SayeghMH; Auriculin Anaritide Acute Renal Failure Study Group: Anaritide in acute tubular necrosis. N Engl J Med 336: 828-834, 1997
39. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ,Hutchison R,Mehrtens JE, Robinson JM, Schollum JBW, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 77: 1020-1030, 2010
40. Hoy WE, Hughson MD, Bertram JF, Douglas-Denton R, Amann K: Nephron number, hypertension, renal disease, and renal failure. J Am Soc Nephrol 16: 2557-2564, 2005
41. Kher A, Meldrum KK, Wang M, Tsai BM, Pitcher JM, Meldrum DR: Cellular andmolecularmechanisms of sex differences in renal ischemiareperfusion injury. Cardiovasc Res 67: 594-603, 2005
42. Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV: Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem 279: 52282-52292, 2004
43. HuM-C, Shi M, Cho HJ, Zhang J, Pavlenco A, Liu S, Sidhu S, Huang LJ-S, MoeOW: The erythropoietin receptor is a downstreameffector of Klothoinduced cytoprotection. Kidney Int 84: 468-481, 2013
44. Coldewey SM, Khan AI, Kapoor A, Collino M, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE, Yaqoob MM, Patel NS, Thiemermann C: Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the b-common receptor. Kidney Int 84: 482-490, 2013
45. Zhu X, Perazella MA: Nonhematologic complications of erythropoietin therapy. Semin Dial 19: 279-284, 2006
46. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P: Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952: 128-134, 2002
47. Grasso G, Sfacteria A, Erbayraktar S, PassalacquaM,Meli F,GokmenN, Yilmaz O, La Torre D, Buemi M, Iacopino DG, Coleman T, Cerami A, Brines M, Tomasello F: Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietinderivative. JNeurosurg Spine 4:310-318,2006
48. BrinesML,GhezziP,Keenan S,Agnello D,deLanerolleNC,CeramiC, ItriLM, Cerami A: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97: 10526-10531, 2000
49. Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W: Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122: 1005-1011, 2008
50. SinclairAM,CoxonA,McCaffery I,KaufmanS,PaweletzK, Liu L, Busse L, Swift S, Elliott S, Begley CG: Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115: 4264-4272, 2010
51. Elliott S, Busse L, Swift S, McCaffery I, Rossi J, Kassner P, Begley CG: Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant 27: 2733-2745, 2012
52. Hand CC, Brines M: Promises and pitfalls in erythopoietin-mediated tissue protection: Are nonerythropoietic derivatives a way forward? J Investig Med 59: 1073-1082, 2011
53. Brines M, Cerami A: The receptor that tames the innate immune response. Mol Med 18: 486-496, 2012
54. Westenfelder C, Arevalo GJ, Crawford PW, Zerwer P, Baranowski RL, Birch FM, Earnest WR, Hamburger RK, Coleman RD, Kurtzman NA: Renal tubular function in glycerol-induced acute renal failure. Kidney Int 18: 432-444, 1980
55. Tögel F, Hu Z,Weiss K, Isaac J, Lange C,Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289: F31-F42, 2005
56. Isaac J, Tögel FE,Westenfelder C: Extent of glomerular tubularization is an indicator of the severity of experimental acute kidney injury in mice. Nephron, Exp Nephrol 105: e33-e40, 2007